Supplementary Table S6 from A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors
Year: 2023
Type: supplementary-materials
Abstract: Differences in baseline protein expression between patients who did (n=3) and did not (n=3) achieve disease control. A table summarizing the differences in baseline levels of protein expression between patients who achieved disease control and those who did not.
Authors: Clinton Yam, Xiaowei Xu, Michael A. Davies, Phyllis A. Gimotty, Jennifer J.D. Morrissette, Michael T. Tetzlaff, Khalida M. Wani, Shujing Liu, Wanleng Deng, Meghan Buckley, Jianhua Zhao, Ravi K. Amaravadi, Naomi B. Haas, Ragini R. Kudchadkar, Anna C. Pavlick, Jeffrey A. Sosman, Hussein Tawbi, Luke Walker, Lynn M. Schuchter, Giorgos C. Karakousis, Tara C. Gangadhar
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361885588